LianBio (LIANY)

OTCMKTS · Delayed Price · Currency is USD
0.253
-0.007 (-2.69%)
Dec 24, 2024, 4:00 PM EST
-94.38%
Market Cap 27.37M
Revenue (ttm) n/a
Net Income (ttm) -87.98M
Shares Out 108.17M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 124,900
Open 0.253
Previous Close 0.260
Day's Range 0.253 - 0.265
52-Week Range 0.241 - 4.990
Beta 0.00
Analysts n/a
Price Target n/a
Earnings Date Mar 27, 2025

About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatme... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 163
Stock Exchange OTCMKTS
Ticker Symbol LIANY
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.